Stay updated on Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page.

Latest updates to the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedA new revision tag 'Revision: v3.4.2' was added, and the page no longer displays the previous government-funding notice or the earlier 'Revision: v3.4.1' text. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check21 days agoChange DetectedA system-wide notice about a lapse in government funding and a site revision from v3.4.0 to v3.4.1 were added. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check28 days agoChange DetectedNew Study Documents entries were added, including the Study Protocol PDF and the Statistical Analysis Plan PDF, with corresponding metadata. A glossary toggle was also introduced on the page to aid understanding.SummaryDifference63%

- Check35 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check65 days agoChange DetectedThe page's location information was reorganized to include a top-level Locations section with Barcelona and Navarre, replacing the previous Barcelona and Navarre Locations entries. The revision version updated to v3.3.3 and the HHS Vulnerability Disclosure link was removed.SummaryDifference0.3%

- Check86 days agoChange DetectedPage revision updated from v3.3.1 to v3.3.2.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page.